
    
      This is a Canadian Post Marketing Observational Study utilizing a prospective cohort design.
      Patients with Prostate Cancer who are prescribed Lupron will be entered into the study cohort
      and will be followed for a maximum of 36 months with recommended assessments at 3, 6, 12, 18,
      24, 30 and 36 months after baseline. Treatment of the patients and follow up will be
      according to the physician's judgment, regional regulations and the product monograph.
    
  